Arbidol 50mg tablets 10
Women's clothing size
With your arms relaxed at your sides, measure around the fullest part of your chest.
Measure around the narrowest part of your natural waist, generally around the belly button. To ensure a comfortable fit, keep one finger between the measuring tape and your body.
Methylphenylthiomethyl-dimethylaminomethyl-hydroxybromindole carboxylic acid ethyl ester
umifenovir hydrochloride monohydrate - 51.75 mg, which corresponds to the content of umifenovir hydrochloride - 50 mg;
excipients: potato starch - 31.86 mg, microcrystalline cellulose - 57.926 mg, povidone (povidone K30) - 8.137 mg, calcium stearate - 0.535 mg, croscarmellose sodium (primellose) - 1.542 mg.
shell composition: hypromellose (hydroxypropyl methylcellulose) - 4.225 mg, titanium dioxide - 1.207 mg, macrogol (polyethylene glycol 4000) - 0.471 mg, polysorbate 80 (twin 80) - 0.097 mg; or Aquarius PrimeBAP318008 White (Aquarius PrimeBAP318008 White) - 6 mg [hypromellose (hydroxypropyl methylcellulose) - 4.225 mg, titanium dioxide - 1.207 mg, macrogol (polyethylene glycol 4000) - 0.471 mg, polysorbate 80 (twin 80) - 0.097 mg].
Specifically suppresses in vitro influenza viruses A and B (Influenza virus A, B), including highly pathogenic subtypes A(H1N1)pdm09 and A(H5N1), as well as other viruses - causative agents of ARVI (Coronavirus), associated with severe acute respiratory syndrome (SARS), rhinovirus (Rhinovirus), adenovirus (Adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (Paramyxovirus)).
According to the mechanism of antiviral action, it belongs to fusion inhibitors (fusion), interacts with hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes.
It has a moderate immunomodulatory effect, increases the body's resistance to viral infections. It has interferon-inducing activity - in a study on mice, the induction of interferons was noted after 16 hours, and high titers of interferons persisted in the blood until 48 hours after administration.
Stimulates cellular and humoral immune responses: increases the number of lymphocytes in the blood, especially T cells (CD3), increases the number of T-helpers (CD4), without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killers (NK cells).
Therapeutic effectiveness in viral infections is manifested in reducing the duration and severity of the course of the disease and its main symptoms, as well as in reducing the incidence of complications associated with viral infection and exacerbations of chronic bacterial diseases.
Refers to low-toxic drugs (LD 50 >4 g/kg). Does not have any negative effect on the human body when administered orally at recommended doses.
Suction and distribution
Quickly absorbed and distributed to organs and tissues. C max in blood plasma when taken at a dose of 50 mg is achieved after 1.2 hours, at a dose of 100 mg - after 1.5 hours.
Metabolism and excretion
Metabolized in the liver.
T 1/2 Is 17-21 hours About 40% is excreted unchanged, mainly with bile (38.9%) and in a small amount of kidneys (0.12%). During the first day, 90% of the administered dose is excreted.
Indications for use
- prevention and treatment in adults and children: influenza A and B, other ACUTE RESPIRATORY VIRAL INFECTIONS;
- complex therapy of acute intestinal infections of rotavirus etiology in children older than 3 years;
- complex therapy of chronic bronchitis, pneumonia and recurrent herpes infection;
- prevention of postoperative infectious complications.
- hypersensitivity to umifenovier or any component preparation;
- children up to 3 years of age;
- I trimester of pregnancy;
- the period of breastfeeding.
Dosage and administration
The drug is taken orally, before meals.
Single dose (depending on age):
|Age||Single dose of the drug, mg umifenovir (tablets)|
|from 3 to 6 years||50 mg (1 tab.)|
|from 6 to 12 years||100 mg (2 tab.)|
|over 12 years old and adults||200 mg (4 tab.)|
|Reading||Scheme of taking the drug|
|In children from 3 years and adults:|
|Non-specific prevention during the epidemic of influenza and other SARS||in a single dose 2 times a week for 3 weeks.|
|Non-specific prophylaxis in direct contact with patients with influenza and other ARVI||in a single dose 1 time / day for 10-14 days.|
|Treatment of influenza and other acute respiratory viral infections||in a single dose 4 times / day (every 6 hours) for 5 days.|
|In children from 3 years:|
|Complex therapy of acute intestinal infections of rotavirus etiology||in a single dose 4 times / day (every 6 hours) for 5 days.|
|In children from 3 years and adults:|
|Complex therapy of chronic bronchitis, pneumonia, herpes infection||in a single dose 4 times / day (every 6 hours) for 5-7 days, then a single dose 2 times a week for 4 weeks|
|Prevention of postoperative infectious complications||in a single dose 2 days before the operation, then on the 2nd and 5th day after the operation|
Reception of the drug begins from the moment the first symptoms of influenza and other ARVI appear, preferably no later than 3 days from the onset of the disease.
If after taking the drug Arbidol ® within 3 days in the treatment of influenza and other SARS, the severity of the symptoms of the disease remains, including high temperature (38 ° C or more), the patient should consult a doctor to assess the validity of taking the drug.
The drug should be used only according to those indications, the method of application and in those doses that are specified in the instructions.
Arbidol ® refers to low-toxic drugs and is usually well tolerated. Side effects are rare, usually mild or moderate and transient.
The incidence of adverse drug reactions is determined in accordance with the WHO classification: very often (>1/10), often (≥1/100, but <1/10), infrequently (≥1/1000, but <1/100), rarely (≥1/10 000, but <1/1000), very rare (<1/10 000), frequency unknown (can not be established from available data).
From the immune system: rarely - allergic reactions.
If any of the side effects indicated in the instructions are aggravated or any other side effects not indicated in the instructions are noted, the patient should inform the doctor about it.
In the treatment of influenza and ARVI, concomitant symptomatic therapy is possible, including taking antipyretic drugs, mucolytic and local vasoconstrictors.
The drug should be stored out of reach of children at a temperature not higher than 25 ° C.
- Dosage form
- 50 mg
- Umifenevir hydrochloride
- Number of tablets
- INN Russian
- Умифеновира гидрохлорид
- Russian title